Dendritic cells genetically engineered to express IL-4 exhibit enhanced IL-12p70 production in response to CD40 ligation and accelerate organ allograft rejection

被引：0
作者：
K Kaneko
Z Wang
S H Kim
A E Morelli
P D Robbins
A W Thomson
机构：
[1] University of Pittsburgh Medical Center,Thomas E. Starzl Transplantation Institute and Department of Surgery
[2] University of Pittsburgh Medical Center,Department of Molecular Genetics and Biochemistry
来源：
Gene Therapy | 2003年 / 10卷
关键词：
dendritic cells; transplantation; gene therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
C57BL/10 (B10; H2b) bone marrow-derived myeloid dendritic cells (DC) propagated in GM-CSF + IL-4 were transduced with r adenoviral (Ad) vectors encoding either control neomycin-resistance gene (Ad-Neo) or murine IL-4 (Ad-IL-4) on day 5 of culture following CD11c immunomagnetic bead purification. Both Ad-Neo- and Ad-IL-4-transduced DC displayed upregulated surface MHC class II and costimulatory molecules (CD40, CD80, CD86). Ad-IL-4 DC secreted higher levels of bioactive IL-12p70 after CD40 ligation or LPS stimulation than either Ad-Neo or unmodified DC. Only Ad-IL-4 DC produced IL-12p70 in primary MLR, in which they induced augmented proliferative responses of naïve allogeneic C3H/HeJ (C3H; H2k) T-cells. Compared with Ad-Neo DC, Ad-IL-4 DC were also more effective in priming naïve allogeneic recipients to exhibit specifically enhanced anti-donor T-cell proliferative and CTL responses. T-cells primed in vivo 7 days previously with Ad-IL-4 DC displayed enhanced secretion of Th2 (IL-4, IL-10) but also higher Th1 cytokine (IFNγ) production following ex vivo challenge with donor alloAg. Moreover, pretreatment of vascularized heart graft recipients with i.v. Ad-IL-4 DC, 1 week before transplant, significantly accelerated rejection and antagonized the therapeutic effect of anti-CD40L (CD154) mAb. These data contrast markedly with recently reported inhibitory effects of autologous Ad-IL-4 DC on autoimmune inflammatory disease.
引用
收藏
页码：143 / 152
页数：9
相关论文
共 60 条
[31]  
Coates PT(2001)Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4 J Clin Invest 107 1275-1284
[32]  
O'Rourke RW(2000)Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis J Virol 74 9617-9628
[33]  
Levy AE(2001)Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathway Transplantation 72 1556-1562
[34]  
Alexander JW(1997)Operational tolerance induced by pretreatment with donor dendritic cells under blockade of CD40 pathway Transplantation 64 1808-1815
[35]  
He XY(2000)Blockade of the CD40–CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival Gene Ther 7 505-510
[36]  
Rabinovitch A(1993)Interleukin-10 produced by recombinant adenovirus prolongs survival of cardiac allografts in rats J Immunol 150 2112-2120
[37]  
Takeuchi T(1992)Anti-IL-4 diminishes in vivo priming for antigen-specific IL-4 production by T-cells J Immunol 148 3820-3829
[38]  
Kato H(2000)IL-4 plays a dominant role in the differential development of Th0 into Th1 and Th2 cells J Exp Med 192 823-833
[39]  
Fanslow WC(2000)Interleukin (IL)-4 is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells J Immunol 165 1877-1881
[40]  
Raisanen-Sokolowski A(2001)IL-4 is a mediator of IL-12p70 induction by human Th2 cells: reversal of polarized Th2 phenotype by dendritic cells Scand J Immunol 53 455-463
123456